Cisplatin based chemotherapy in patients with advanced differentiated thyroid carcinoma refractory to I131 treatment

Abstract

Purpose: The purpose of the study was to evaluate the activity and toxicity of cisplatin based chemotherapy in patients with advanced differentiated thyroid cancer refractory to radioactive iodine (I131). Patients and Methods: We retrospectively reviewed the records of 20 patients with advanced thyroid cancer treated with cyclophosphamide 500 mg/m 2 on day 1, doxorubicin 50 mg/m 2 day 1 and cisplatin 50 mg/m 2 day 1 of a 21 days cycle community-acquired pneumonia (CAP) or the same regimens without cyclophosphamide adriamycin and Platinum (AP). Results: Median age of patients was 65 years (range 54-80). The majority of patients had lung metastases (60%). 4 (20%) patients achieved a partial response. Stable disease was achieved in 6 (30%) patients. Overall clinical response was 50%. Mean follow-up time was 8 months (range 4-17). Mean progression free survival was 6 months (range 3-12). Mean overall survival was 9 months (range 4-17). Patients with partial remission had a mean time to disease progression of 9 months. 4 (20%) patients had Grade 3 or 4 neutropenia. One patient had febrile neutropenia. Mild neuropathy was recorded in 5 (25%) of patients. There were no treatment related deaths. Conclusion: The combination of CAP is active in the treatment of advanced thyroid cancer with tolerable toxicity. This regimen may still be used in patients who could not be treated with targeted therapy or combined with antiangiogenic drugs in future studies.

Keywords

Advanced - chemotherapy - differentiated - thyroid cancer

• References

• 1 Green LD, Mack L, Pasieka JL. Anaplastic thyroid cancer and primary thyroid lymphoma: A review of these rare thyroid malignancies. J Surg Oncol 2006;94:725-36.
• 2 Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the surveillance, epidemiology and end results (SEER) program 1973-1991. Cancer 1997;79:564-73.
• 3 Sherman SI. Thyroid carcinoma. Lancet 2003;361:501-11.
• 4 Alexieva-Figusch J, Van Gilse HA, Treurniet RE. Chemotherapy in carcinoma of the thyroid: Retrospective and prospective. Ann Radiol (Paris) 1977;20:810-3.
• 5 Gottlieb JA, Hill CS Jr. Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N Engl J Med 1974;290:193-7.
• 6 Sokal M, Harmer CL. Chemotherapy for anaplastic carcinoma of the thyroid. Clin Oncol 1978;4:3-10.
• 7 Shimaoka K. Adjunctive management of thyroid cancer: Chemotherapy. J Surg Oncol 1980;15:283-6.
• 8 Suzumura K, Koike A, Naruse T, Matsumoto K, Nagata H, Kojima T, et al. Antitumor effect of UFT against differentiated thyroid cancer. Gan To Kagaku Ryoho 1994;21:2485-9.
• 9 Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985;56:2155-60.
• 10 Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J Clin Oncol 2008;26:4708-13.
• 11 Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-9.
• 12 Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
• 13 Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
• 14 Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20 th century: A period analysis. Lancet 2002;360:1131-5.
• 15 Zidan J, Hefer E, Iosilevski G, Drumea K, Stein ME, Kuten A, et al. Efficacy of I131 ablation therapy using different doses as determined by postoperative thyroid scan uptake in patients with differentiated thyroid cancer. Int J Radiat Oncol Biol Phys 2004;59:1330-6.
• 16 Pittas AG, Adler M, Fazzari M, Tickoo S, Rosai J, Larson SM, et al. Bone metastases from thyroid carcinoma: Clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid 2000;10:261-8.
• 17 Benker G, Hackenberg K, Hoff HG, Seeber S, Ebke J, Windeck R, et al. Combined doxorubicin and bleomycin treatment of metastasising thyroid carcinoma: Results in 21 patients (author′s transl)]. Zytoststische kombinationshehandlung metastasierender schilddrusen karzinome mit doxorubicin und bleomycin. Dtsch Med Wochenschr 1977;102:1908-13.
• 18 Tuttle RM, Fleisher M, Francis GL, Robbins RJ. Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. J Clin Endocrinol Metab 2002;87:1737-42.
• 19 Bauer AJ, Terrell R, Doniparthi NK, Patel A, Tuttle RM, Saji M, et al. Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. Thyroid 2002;12:953-61.
• 20 NCCN clinical practice guidelines in oncology (NCCN guidelines). Thyroid carcinoma. PAP-7. Version I, 2013. Available from: http://www.NCCN.org. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines Version 1, 2013
• 21 Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.